Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective upped by Barclays from $24.00 to $27.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 28.57% from the company’s current price.
A number of other equities analysts have also recently weighed in on the company. Weiss Ratings raised Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. JPMorgan Chase & Co. boosted their price target on shares of Bausch + Lomb from $16.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 29th. Deutsche Bank restated a “hold” rating and set a $20.00 price objective on shares of Bausch + Lomb in a research report on Thursday, October 29th. UBS Group began coverage on shares of Bausch + Lomb in a research note on Thursday, July 30th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Zacks Research upgraded Bausch + Lomb from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $21.08.
Bausch + Lomb Price Performance
Shares of NYSE BLCO opened at $21.00 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.56 and a quick ratio of 1.04. The stock has a market capitalization of $7.52 billion, a price-to-earnings ratio of -67.53, a PEG ratio of 0.56 and a beta of 0.52. The firm’s 50 day simple moving average is $18.04 and its 200-day simple moving average is $16.88. Bausch + Lomb has a 12 month low of $14.44 and a 12 month high of $21.40.
Bausch + Lomb (NYSE:BLCO – Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.13. Bausch + Lomb had a negative net margin of 2.05% and a positive return on equity of 5.01%. The firm had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.37 billion. During the same period in the previous year, the business posted $0.18 EPS. The business’s revenue was up 7.3% compared to the same quarter last year. Analysts expect that Bausch + Lomb will post 0.94 EPS for the current year.
Insiders Place Their Bets
In other news, CAO Frederick Munsch sold 112,015 shares of the stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $20.48, for a total value of $2,294,067.20. Following the completion of the sale, the chief accounting officer owned 45,831 shares of the company’s stock, valued at $938,618.88. This represents a 70.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.45% of the stock is owned by insiders.
Institutional Trading of Bausch + Lomb
Several institutional investors have recently made changes to their positions in BLCO. State of Wyoming lifted its holdings in Bausch + Lomb by 6.9% in the third quarter. State of Wyoming now owns 13,772 shares of the company’s stock valued at $234,000 after acquiring an additional 887 shares during the last quarter. Handelsbanken Fonder AB grew its position in Bausch + Lomb by 5.3% in the second quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock worth $364,000 after acquiring an additional 1,100 shares during the period. Royal Bank of Canada grew its position in Bausch + Lomb by 67.1% in the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock worth $58,000 after acquiring an additional 1,468 shares during the period. Roxbury Financial LLC acquired a new stake in Bausch + Lomb during the third quarter worth $33,000. Finally, R Squared Ltd increased its stake in Bausch + Lomb by 46.0% during the third quarter. R Squared Ltd now owns 17,452 shares of the company’s stock worth $297,000 after acquiring an additional 5,502 shares during the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.
Bausch + Lomb Company Profile
Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.
Further Reading
- Five stocks we like better than Bausch + Lomb
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
